About DXY

DXY

DXY, published at dxy.cn and known in Chinese as Dingxiangyuan — "Lilac Garden" — is a Hangzhou-based online medical platform founded in 2000 by Li Tiantian. It began as an online community where Chinese physicians could discuss clinical findings and professional questions, and it grew into one of the largest physicians' online communities in the world, combining medical news, drug databases and professional services for doctors with a consumer health service, Dingxiang Yisheng (Dr. Lilac), for the public. Few Chinese health websites are cited as routinely by international medical and business media, a position DXY cemented in early 2020 when its real-time COVID-19 dashboard became a reference source for tracking the outbreak.

Founding and the physicians' community

DXY.cn was established on 23 July 2000 by Tiantian Li, a physician turned entrepreneur who remains the company's chairman. It is more of a vertical community than a traditional social network: a professional space where physicians, other health-care professionals, pharmacies and medical facilities exchange insight, discuss new clinical findings and report unusual cases. That professional-first design is the core of the business. A general health portal competes for the attention of patients; DXY built its position by becoming part of the working life of doctors themselves. The scale that followed is documented across its funding announcements: Wikipedia's summary describes more than 3.2 million members, while Caixin's report of its 2020 funding round described tens of millions of users and over 5.5 million medical professionals, among them more than 2.1 million physicians. KrASIA, reporting the same round, quoted the company's own framing that roughly seven out of every nine doctors in China have a DXY account.

Services for medical professionals

Around the community, DXY built a set of professional tools and businesses that its company descriptions group into several lines. Its commercial operations have included Biomart, a platform for biomedical e-commerce; JobMD, a platform for health-care job searching, matching and headhunting; and DXY Survey, a market-research service drawing on its professional user base. Alongside these sit the reference functions that made the site a daily utility for clinicians — medical news, literature and drug information, and discussion forums organised by specialty. For pharmaceutical and life-science companies, that combination of reach and professional trust made DXY a channel for reaching Chinese doctors that few rivals could match, and advertising and services aimed at those corporate clients became a central part of its model alongside its recruitment and research businesses.

Dingxiang Yisheng and the consumer turn

In 2012 DXY began expanding toward consumers, the move that turned a professional community into a broader health platform. The consumer-facing brand, Dingxiang Yisheng — rendered in English as DX Doctor or Dr. Lilac — offers health and wellness information and medical consultation services to the public, drawing its authority from the physician network behind it. DXY.com, affiliated with DXY.cn, operates as a telemedicine platform. In July 2020 the company formalised the structure as a "dual-core strategy" connecting the public-facing DX Doctor brand with the physician-facing DXY.cn, explicitly framing its model as driven by both ends — doctors and the public — with professional expertise as the shared asset. The company also developed in-person clinics where patients could receive care, extending the brand from information into service delivery.

The COVID-19 dashboard

DXY's defining public moment came in January 2020. Working with Tencent's WeChat, DXY was among the first — by several accounts the first — to roll out a real-time COVID-19 information dashboard and heat map showing confirmed cases for mobile users, at a moment when reliable, current numbers on the new outbreak were scarce. The tracker, built from media and government reports and updated in near real time, became a major source of data on the pandemic inside China and beyond: researchers at the US National Institutes of Health used DXY.cn data — cases reported between 13 and 31 January 2020 — for an early epidemiological analysis published in The Lancet Digital Health, which examined how reporting delays in mainland China fell from five days to two days after 18 January 2020. For an online community founded two decades earlier for doctors, becoming part of the evidentiary base of the first pandemic studies was a striking validation of its position in Chinese health information.

Funding history

DXY's growth was financed through a long sequence of venture rounds documented in its funding coverage. It raised a $2 million Series A from DCM in January 2010, approximately $10 million in a Series B led by Shunwei Capital — the fund backed by Xiaomi co-founder Lei Jun — with DCM participating, in December 2012, and $70 million in a Series C from Tencent in September 2014, the start of Tencent's long association with the company. A $100 million Series D in 2018 took DXY to unicorn status. In December 2020 it closed a $500 million Series E led by Trustbridge Partners, with Tencent and GL Ventures (Hillhouse) participating, bringing lifetime fundraising to roughly $680 million. Announcing the round, Li Tiantian said the company would consolidate its core advantage in its network of medical professionals and deepen collaboration with doctors, hospitals, life-science companies and other professional users — on both the physician and consumer sides of the platform.

Scrutiny and the limits of the model

DXY's history also records the constraints on internet health care in China. Reuters reported in the mid-2010s that the company was curbing plans to connect doctors and patients online through public hospitals, citing a lack of policy support and the obstacles of working with China's large, fragmented public hospital system; Li told Reuters the obstacles were not market, capital or technology — all of which he considered developed — but implementation on the ground. The company has also faced content pressure: in 2022, after DXY questioned the value of Lianhua Qingwen, a government-backed herbal remedy marketed as a COVID-19 treatment — coverage that contributed to a plunge in the producer's shares — its social-media accounts were suspended from posting for "violation of relevant laws and regulations" and its WeChat accounts stopped updating for a period, an episode reported internationally by AFP. The two episodes together describe the operating environment of a Chinese medical platform precisely: commercially powerful, professionally trusted, and still bounded by hospital-system realities and by official sensitivity around medical claims.

DXY as a working news source for medicine

Beyond its community functions, DXY operates as a newsroom-grade information source for Chinese medicine, and outside researchers and journalists treat it that way. Its news and data feeds stream material from Chinese health agencies — the property that led US National Institutes of Health researchers to mine DXY.cn for their early COVID-19 case analysis — and its founder's views on Chinese health reform have been sought by international wire services, including Reuters' reporting on the obstacles facing internet health care in China, in which Li Tiantian spoke on the record about hospital-system constraints. That dual standing — a professional community that also functions as a citable news and data source — distinguishes DXY from purely social health platforms and from consumer health portals whose content doctors themselves do not use.

Scale and position

By the time of its 2020 funding round, reporting on DXY put its reach at about 130 million consumers, more than 9,000 medical organisations and a registered user base of about 20 million across its services — figures that vary by which part of the platform is being counted but consistently place it among the largest health platforms in China and, for physicians specifically, among the largest professional medical communities anywhere. Based in Hangzhou, Zhejiang, and published at dxy.cn, DXY is best understood as three things built on one asset: a news and reference service Chinese doctors actually use, a set of professional businesses — recruitment, e-commerce and research — monetising that use, and a consumer health brand borrowing the doctors' credibility. Its COVID-19 dashboard made that asset visible to the world; the community underneath it is why the company has endured since 2000.